RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion.
CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫逃逸是肿瘤生长和存活的关键策略,肿瘤微环境促进肿瘤免疫逃逸和癌症进展。CD47是一种在多种癌细胞类型中高表达的跨膜蛋白,与其配体SIRPα和TSP-1相互作用,诱导免疫耐受,使肿瘤细胞能够逃避免疫监视和免疫细胞的吞噬作用。了解驱动CD47信号传导的途径及相关激活因子至关重要。在本综述中,我们讨论CD47与其配体SIRPα和TSP-1之间的相互作用;它们在抑制免疫细胞(巨噬细胞、树突状细胞(DCs)、胶质细胞、T细胞、NK细胞等)功能中的作用;以及所涉及的机制。
此外,我们还探讨肿瘤微环境中因素对CD47介导免疫逃逸的影响,包括TNF-α、IFN-γ、ILs、HIF-1、癌基因、异柠檬酸脱氢酶1、代谢酶和外泌体。近期靶向CD47用于癌症治疗的单克隆抗体药物已显示出副作用并造成经济损失。研究人员可以探索替代方法,例如设计副作用最小的靶向药物,或研究其他相关分子或途径。联合治疗以及对CD47分子机制的进一步研究可能为抗肿瘤药物开发提供新方向。
Immune evasion is a crucial strategy for tumor growth and survival, with the tumor microenvironment facilitating tumor immune evasion and cancer progression. CD47, a transmembrane protein highly expressed in various cancer cell types, interacts with its ligands SIRPα and TSP-1 to induce immune tolerance, enabling tumor cells to evade immune surveillance and phagocytosis by immune cells.
Understanding the pathways driving CD47 signaling and related activation factors is essential. In this review, we discuss the interactions between CD47 and its ligands SIRPα and TSP-1; their roles in inhibiting the functions of immune cells (macrophages, dendritic cells (DCs), glial cells, T cells, NK cells, etc .) ; and the mechanisms involved.
Furthermore, we also explore the influence of factors within the tumor microenvironment, including TNF-α, IFN-γ, ILs, HIF-1, oncogenes, isocitrate dehydrogenase 1, metabolic enzymes, and exosomes, on CD47-mediated immune evasion. Recent monoclonal antibody drugs targeting CD47 for cancer treatment have shown side effects and cause economic losses.
Researchers can explore alternative approaches, such as designing targeted drugs with minimal side effects or investigating other related molecules or pathways. Combination therapy and further research into the molecular mechanisms of CD47 could offer new directions for antitumor drug development.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。